TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00581594

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Graft-augmented colporrhaphy
Description: Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional posterior colporrhaphy
Description: Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
Study: NCT02678221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Study: NCT03158337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study: NCT00467818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosage as that of omega 3 fatty acids
Study: NCT06776276

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi exercises
Description: Tai-chi (TC) is a kind of CAM Qigong exercises, is a type of classic Chinese martial arts. It entails deliberate, slow-motion physical movements that are done alongside inward concentration, awareness of breathing, and the inherent power or energy in the body. It promotes general purposes of health and spirituality. It is generally accessible and offered to older people in public places.
Study: NCT00149071

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Transcraniel Magnetic Stimulation active and sham

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Transcraniel Magnetic Stimulation active and sham

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: active Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: active Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: daily for three weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: daily for three weeks
Study: NCT00574301

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Removal and Margin Ablation
Description: Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
Study: NCT03404206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium (Aleve, BAY117031)
Description: 220 mg x 2 tablets, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen (Advil)
Description: 200 mg x 2 tablets, oral, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, 2 tablets, oral, single dose
Study: NCT02756000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dobutamine stress echocardiography
Description: Echocardiographic stress test of provoked myocardial ischemia using dobutamine
Study: NCT02280421

Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151 400mg + 100mg ciclosporin

Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151 1200mg + 100mg ciclosporin
Study: NCT03275701

Intervention type: DRUG
Group type: OTHER
Intervention: Triumeq
Description: Open Label, Switch to Triumeq (ABC/DTG/3TC)
Study: NCT03712969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenlingcao Oral Liquid
Description: Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
Study: NCT01193517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine MTD
Description: Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
Study: NCT04522414

Intervention type: OTHER
Intervention: cries longitudinally registered
Description: Their cries will be longitudinally registered from the age of birth to the return home using an automatic record device: Song Meter SM4.
Study: NCT01360450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine HCL
Description: At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between \< 9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
Study: NCT02115256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Terbutaline
Description: 0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nitroglycerine
Description: The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
Study: NCT02307409

Intervention type: OTHER
Intervention: Sonoclot/TEG test
Description: The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis

Intervention type: OTHER
Intervention: Sonoclot/TEG test
Description: The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
Study: NCT00146770

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme
Description: Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aldurazyme
Description: 0.58 mg/kg Aldurazyme every week for 208 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo for 26 weeks
Study: NCT04818021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Sensorimotor adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Skin Stretch
Description: Facial skin stretch

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial Skin Stretch
Description: Facial skin stretch
Study: NCT04895618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia GVL
Description: Single treatment with the Erchonia GVL to the neck and shoulders. The treatment applies 520 nanometers (nm) green diode light and 405 nm violet diode light simultaneously.
Study: NCT00617435

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vaccenic acid enriched diet
Description: The experimental milk fat, entitled vaccenic acid enriched milk fat (VAMF), has been obtained by feeding cows with a diet containing sunflower oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elaidic acid enriched diet
Description: Mixture of vegetable oils (including partially hydrogenated oils)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control diet
Description: Mixed of different oil
Study: NCT02056275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition supplement + dietary counseling
Description: Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: Dietary counseling provided at each study visit by study dietitian.
Study: NCT00566709

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cells transfusion
Description: Patients will be transfused (one to one red blood cells unit transfusion)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red blood cells transfusion
Description: Patients will be transfused (one to one red blood cells unit transfusion)
Study: NCT03563027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Incentive Gamification
Description: Game-based intervention with points and levels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Incentive Gamification
Description: Game-based intervention with points and levels

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Sponsor
Description: Participants select a support sponsor to receive weekly updates on progress in the game

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Sponsor
Description: Participants select a support sponsor to receive weekly updates on progress in the game

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Participants receive a loss-framed financial incentive allocated upfront each week and financial incentives taken away each day the goal is not met
Study: NCT02135874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT00757666

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate adaptive pacemaker
Description: Accelerometer sensor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate adaptive pacemaker
Description: Minute ventilation sensor
Study: NCT04497324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.
Study: NCT01882400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment
Description: Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
Study: NCT03679754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: * 2.0 x 10\^11 viral particles (vp) per injection~* intratumoral injection of Ad-RTS-hIL-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veledimex
Description: * 20mg/day~* 15 oral daily doses of veledimex
Study: NCT01626378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237
Description: TRx0237 100 mg tablet will be administered twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
Study: NCT02052128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onapristone
Study: NCT00359437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satavaptan
Description: oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration once daily
Study: NCT01269983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Description: 8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fascial Manipulation
Description: 8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
Study: NCT03681106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tex
Description: Kinesio Tex tape on the operated limb
Study: NCT01337050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03446962
Description: PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
Study: NCT00494806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocking Chair Intervention
Description: Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
Study: NCT02305420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmbryoGen/ BlastGen media
Description: Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cook sequential media
Description: Standard Cook IVF media will be used in the control arm
Study: NCT03171714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Derma-Stent
Description: The novel device will facilitate self removal by patients, as it has a narrower profile, and, as a nonabsorbent material, will not become saturated with bodily fluids. Although it will not absorb body fluids

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care, cotton gauze packing
Description: Standard gauze packing used to pack a drained abscess.
Study: NCT02668302

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Steroid-eluting sinus implant
Description: PROPEL (Intersect ENT, Inc., Menlo Park, CA), containing 370μg of mometasone furoate gradually released over 30 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-op standard of care
Description: Post-op standard of care including debridement, irrigation, and/or topical steroids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-op standard of care
Description: Post-op standard of care including debridement, irrigation, and/or topical steroids
Study: NCT01189240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study: NCT03711708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoloft Oral Solution
Description: Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft tablets
Description: Reference Product: 50 mg sertraline administered as 1x Zoloft 50 mg tablet
Study: NCT01189240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT02128854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablets Intervention
Description: The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes. Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors. Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
Study: NCT02744729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2
Description: For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
Study: NCT04273529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 100mg，po，qn，for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mg，po，qn，for 14 days.
Study: NCT04177095

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Allosure
Description: Monthly monitoring of dd-cfDNA levels in blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression reduction
Description: Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trugraf
Description: Monthly monitoring of Trugraf result
Study: NCT01024504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles